Annexon, Inc.
NASDAQ:ANNX
4.84 (USD) • At close January 8, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Annexon, Inc. |
Symbool | ANNX |
Munteenheid | USD |
Prijs | 4.84 |
Beurswaarde | 515,914,960 |
Dividendpercentage | 0% |
52-weken bereik | 3.86 - 8.4 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Douglas Love Esq., J.D. |
Website | https://www.annexonbio.com |
An error occurred while fetching data.
Over Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)